← back to search

Ray Moynihan

Bond University · AU
Area of research
Pharmacology · Economics and Econometrics
Research interest
Research interests include Pharmaceutical industry and healthcare, Healthcare cost, quality, practices, Health Systems, Economic Evaluations, Quality of Life, and Pharmaceutical Economics and Policy.
h-index
39
citations
8,014
works
215
NIH funding
primary concept
email

Recent publications

Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review
BMJ Open 2021cited by 1,417position: firstdoi
Financial ties between leaders of influential US professional medical associations and industry: cross sectional study
BMJ 2020cited by 77position: firstdoi
Pathways to independence: towards producing and using trustworthy evidence
BMJ 2019cited by 109position: firstdoi
Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study
BMC Cancer 2018cited by 72position: middledoi
Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences
JAMA Otolaryngology–Head & Neck Surgery 2018cited by 70position: middledoi
Australia is responding to the complex challenge of overdiagnosis
The Medical Journal of Australia 2018cited by 24position: firstdoi
Words do matter: a systematic review on how different terminology for the same condition influences management preferences
BMJ Open 2017cited by 141position: middledoi
Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study
Thyroid 2017cited by 76position: middledoi
Walking the tightrope: communicating overdiagnosis in modern healthcare
BMJ 2016cited by 108position: middledoi
Public Opinions about Overdiagnosis: A National Community Survey
PLoS ONE 2015cited by 73position: firstdoi
How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a randomised comparison within a national community survey
BMJ Open 2015cited by 57position: middledoi
Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased
BMJ 2013cited by 150position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Kirsten McCaffery · The University of Sydney8 papers (2015–2018)Brooke Nickel · New South Wales Department of Health6 papers (2015–2018)Jolyn Hersch · The University of Sydney3 papers (2015–2016) · 3 papers (2017–2018) · 2 papers (2019–2021)Jenny Doust · Queensland Health2 papers (2013–2015)Susan J. Jordan · The University of Queensland2 papers (2017–2018) · 2 papers (2020–2021)Stacy M. Carter · University of Wollongong2 papers (2016–2018)Rachelle Buchbinder · Monash Health1 papers (2018–2018) · 1 papers (2020–2020)Mark Jones · Indiana University School of Medicine1 papers (2021–2021)Sharon Sanders · Florida International University1 papers (2021–2021)Adrian Edwards · University of Oslo1 papers (2016–2016) · 1 papers (2018–2018)Elaine Beller · University of Queensland1 papers (2015–2015)Adam G. Dunn · University of Sydney1 papers (2020–2020)Thomas Dakin · University of Sydney1 papers (2018–2018) · 1 papers (2021–2021)Fiona Godlee · London School of Hygiene & Tropical Medicine1 papers (2019–2019)